Price Alert: Shares of Clovis Oncology (CLVS) Trade 7.32% Lower at Midday June 22

Equities Staff  |

Clovis Oncology Inc (NASDAQ: CLVS) shares are down 7.32%, or $0.12 per share, as on 11:52:12 est today. After Opening the Day at $1.74, 23,652,215 shares of Clovis Oncology have been traded today and the stock has ranged between $1.84 and $1.50.  

Already this year the company has a YTD change of 39.48%.

Clovis Oncology expects its next earnings on 2022-08-03.

For technical charts, analysis, and more on Clovis Oncology visit the company profile.

About Clovis Oncology Inc

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.

To get more information on Clovis Oncology Inc and to follow the company's latest updates, you can visit the company's profile page here: Clovis Oncology Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content